1. Introduction {#sec1}
===============

Uveitis is a sight-threatening disease unless treated adequately. Administration of systemic corticosteroids and immunosuppressive agents is standard in the management of ocular inflammatory diseases, including uveitis.[@bib1] More recently, biologics such as tumor necrosis factor (TNF)-α inhibitors have been recommended by expert panels as a new option for the management of ocular inflammatory disorders.[@bib2] Adalimumab is a TNF-α inhibitor, and its efficacy and safety in patients with non-infectious uveitis have been demonstrated by international clinical trials.[@bib3], [@bib4], [@bib5] Significant effects of adalimumab on Behçet\'s disease have also been reported.[@bib6]^,^[@bib7] However, biologics can cause a variety of adverse side effects, such as infection and lymphoma. Another important complication caused by TNF-α inhibitors is interstitial lung disease, which has been reported in patients with psoriasis and rheumatoid arthritis.[@bib8]^,^[@bib9]

Krebs von den Lungen (KL)-6 is a mucopolysaccharide produced by type 2 pneumocytes, and has been used as a specific serum marker of interstitial lung disease.[@bib10], [@bib11], [@bib12] Values higher than 500 U/ml suggest the possibility of interstitial pneumonia and values higher than 1000 U/ml are considered to indicate active interstitial pneumonia.[@bib13] Although the usefulness and reliability of serum KL-6 monitoring during treatment with anti-TNF-α agents has been suggested in patients with rheumatoid arthritis,[@bib14] no cases describing the monitoring of serum KL-6 in patients with uveitis on anti-TNF-α agents appear to have been reported. Here, we report the case of Behçet\'s disease treated using adalimumab, in which serum KL-6 levels were monitored during the therapy. Serum KL-6 levels elevated during treatment and returned to baseline soon after cessation of adalimumab.

2. Case {#sec2}
=======

A 67-year-old man complained of decreased vision in both eyes and was referred to our eye hospital. He had been treated for uveitis in the left eye by a local ophthalmologist two years earlier. He also had past histories of infectious pneumonia, gout, sinusitis, and osteoarthritis of the knee.

At the initial presentation, best-corrected visual acuity (BCVA) was 1.5 in the right eye and 0.05 in the left eye, and intraocular pressure was 8 mmHg bilaterally. Slit-lamp examination disclosed 2+ cells, 2+ flare in the anterior chamber of both eyes. Angle hypopyon was observed on gonioscopic examination of the left eye. Ophthalmoscopic examinations disclosed 1+ vitreous opacities and retinal vasculitis in both eyes and neovascularization around the optic disc and degenerative changes in the macular area of the left eye. Fluorescein angiography (FA) showed diffuse, fern-like dye leakage in both eyes and macular degeneration in the left eye. Systemic examinations yielded essentially normal results and excluded infectious diseases. The patient was positive for HLA-B51, but negative for HLA-A26. The patient had experienced recurrent episodes of oral ulceration, but no genital ulcers or cutaneous lesions. Based on these findings, the patient was diagnosed with incomplete-type Behçet\'s disease according to the Japanese diagnostic criteria.[@bib15]

Betamethasone instillation (0.1%) and 40 mg/day of oral prednisolone were initiated and the dose of prednisolone was gradually decreased. When prednisolone was reduced to 5 mg/day, he developed macular edema in the right eye and erythema nodosum in the skin. Cyclosporin (150 mg/day) was added, and uveitis became inactive for one year thereafter. However, uveitis eventually exacerbated even with prednisolone (15 mg/day) and cyclosporine (150 mg/day), and the patient developed a cataract in the right eye. BCVA decreased to 0.9 in the right eye and 0.01 in the left eye ([Fig. 1](#fig1){ref-type="fig"}). Because of the poorly controlled uveitis and the necessity for cataract surgery in the right eye, administration of adalimumab was considered for the patient, and routine systemic examinations were performed in preparation for administration of biologics. Hematological examinations showed no abnormalities other than a slightly high serum concentration of KL-6, at 606 U/ml. He had no finding of tuberculosis or interstitial pneumonia in terms of either clinical manifestations or computed tomography (CT). We then initiated adalimumab treatment, administering 80 mg as an initial dose, and thereafter biweekly 40 mg together with prednisolone (15 mg/day), instead of cyclosporine. Soon after this therapy conversion, uveitis activity became well controlled and cataract surgery with implantation of an intraocular lens was successfully performed at 6 months after adalimumab initiation.Fig. 1Fundus photos and fluorescein angiography of the patient before starting treatment with adalimumab.Fluorescein angiography shows bilateral severe, broad retinal vasculitis and swelling of the optic disc.Fig. 1

After adalimumab was initiated, systemic examinations to monitor adverse effects of adalimumab including serum KL-6 were periodically performed. The level of serum KL-6 gradually elevated to 1002 U/ml at 6 months after adalimumab initiation and 1277 U/ml at 9 months ([Fig. 2](#fig2){ref-type="fig"}). The patient showed no abnormal respiratory symptom and chest CT scan was normal although laboratory test showed that white blood cell count was elevated to 10,400 cells/mm^3^. We decided to discontinue adalimumab and convert to the previous therapy of cyclosporine (100 mg/day) four months after cataract surgery, because of the possible risk of interstitial lung disease developing in patients with high serum KL-6. Uveitis activity was kept stable even after converting adalimumab to cyclosporine ([Fig. 3](#fig3){ref-type="fig"}). BCVA improved to 1.5 in the right eye and 0.08 in the left eye. Serum levels of KL-6 returned to the baseline level, at 483 U/ml 5 months after cessation of adalimumab ([Fig. 2](#fig2){ref-type="fig"}). White blood cell count decreased to normal and findings on follow-up chest CT showed no interstitial pneumonia.Fig. 2Changes to serum KL-6 in the patient treated with adalimumab. Serum KL-6 was elevated after initiating treatment with adalimumab.Serum KL-6 continued to elevate during treatment and decreased after discontinuation.Fig. 2Fig. 3Fundus photos and fluorescein angiography of the patient 1 month after treatment with adalimumab.Fluorescein angiography showed that bilateral retinal vasculitis was decreased compared to before treatment with adalimumab.Fig. 3

3. Discussion {#sec3}
=============

This report describes elevated serum KL-6 levels in a patient with Behçet\'s disease during biweekly adalimumab administration, and these elevated levels of serum KL-6 normalized following discontinuation of adalimumab without interstitial lung disease developing. To the best of our knowledge, this is the first report to describe a transient elevation of serum KL-6 in a case of uveitis treated with TNF-α inhibitor.

KL-6 is a sialylated carbohydrate antigen of Mucin 1, secreted from bronchiolar epithelial cells, bronchial gland cells, and type 2 alveolar epithelial cells. Clinically, elevation of serum KL-6 has been observed in patients with lung injuries where proliferation or regeneration of type 2 alveolar epithelial cells takes place.[@bib16] Ohnishi et al. reported KL-6 as a highly sensitive and specific predictor of interstitial lung disease.[@bib17] Yanaba et al. revealed that mean KL-6 concentration was increased by 20% after 1 year of treatment with adalimumab for psoriasis.[@bib8] Another report in patients with rheumatoid arthritis described elevation of serum KL-6 with fibrotic progression in the lung at nine months after initiation of adalimumab, i.e., an increase of serum KL-6 in 22.2% of patients.[@bib18] Additionally, KL-6 values could also increase with use of infliximab, other TNF-α-inhibiting biologics, without clinical pulmonary events.[@bib8]^,^[@bib19] In the current patient, serum KL-6 was increased by more than 200% at 6 months after adalimumab initiation. Taken together, serum KL-6 may increase at around 6--12 months after adalimumab initiation, if an increase is going to occur. Although the current patient did not develop interstitial pneumonia, discontinuation of adalimumab based on results from serum KL-6 monitoring might have prevented the development of interstitial pneumonia in this patient.

The baseline level of serum KL-6 in the current patient was relatively high and this was considered related to the medical history of pneumonia. Adalimumab was given to the patient despite the relatively high serum KL-6 level for the following reasons: 1) conventional treatment with prednisolone and cyclosporine had not achieved good control of uveitis activity; 2) only the eye with useful vision had developed a cataract and required cataract surgery; 3) despite the relatively high level of serum KL-6, the patient had no symptoms of pneumonia or abnormalities on CT examination of the lungs. In fact, surgical interventions such as cataract surgery are known to cause severe inflammatory reactions soon after surgery.[@bib20] In this patient, uveitis activity was well controlled by adalimumab and cataract surgery was successfully performed without severe inflammatory reactions. However, serum KL-6 gradually elevated and increased to over 1000 U/ml ([Fig. 2](#fig2){ref-type="fig"}). Some previous reports have demonstrated spontaneous decreases in elevated serum KL-6 without cessation of TNF-α inhibitors.[@bib14]^,^[@bib19] In the current case, however, serum KL-6 levels kept increasing and reached over 1000 U/ml, which is the level predicting interstitial pneumonia.[@bib13] The decision was therefore made to discontinue adalimumab. The kinetics of serum KL-6 indicate a significant association between the elevation of serum KL-6 and adalimumab, although the precise mechanisms by which TNF-α inhibitors induce serum KL-6 elevation have not been well investigated. The present case thus implies the clinical importance of monitoring serum KL-6 in patients with non-infectious uveitis being treated with adalimumab and other TNF-α-inhibiting biologics.
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